Consolidated Planning Corp Has $669,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Consolidated Planning Corp boosted its position in Eli Lilly and Company (NYSE:LLY) by 14.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,147 shares of the company’s stock after purchasing an additional 141 shares during the quarter. Consolidated Planning Corp’s holdings in Eli Lilly and Company were worth $669,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares during the last quarter. Morgan Stanley increased its position in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after purchasing an additional 83,915 shares during the last quarter. Northern Trust Corp increased its position in shares of Eli Lilly and Company by 3.6% during the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after purchasing an additional 355,317 shares during the last quarter. International Assets Investment Management LLC increased its position in shares of Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after purchasing an additional 7,330,815 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Eli Lilly and Company by 2.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 4,435,311 shares of the company’s stock worth $2,382,339,000 after purchasing an additional 88,016 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $8.64 during trading on Friday, reaching $733.51. 2,009,249 shares of the company traded hands, compared to its average volume of 2,265,427. The company’s 50 day moving average is $761.79 and its two-hundred day moving average is $666.67. The firm has a market capitalization of $696.95 billion, a PE ratio of 126.47, a PEG ratio of 1.60 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52 week low of $380.77 and a 52 week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.09 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on LLY. BMO Capital Markets boosted their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a report on Monday, April 15th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Finally, Bank of America boosted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.